US · Healthcare · Biotechnology
EPS came in at -0.78 against a street estimate of -0.64 — a miss of 21.9%.
Analysts rate BridgeBio Pharma Inc a buy (16 buy, 3 hold, 0 sell out of 19) with an average price target of $109.10.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.27% |
| Kohlberg Kravis Roberts & Co LP | 6.78% |
| HHG PLC | 6.74% |
| Viking Global Investors LP | 6.06% |
| Farallon Capital Management, L.L.C. | 4.79% |
| Vanguard Portfolio Management, LLC | 4.13% |
| Vanguard Capital Management, LLC | 3.97% |
| Wellington Management Company LLP | 2.72% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 BRIDGEBIO PHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Document date: August 31, 2026 • Company: BridgeBio Pharma, Inc. (NASDAQ: BBIO) • Headq | 2026-08-31 |
| Material agreement · Q3 2026 BRIDGEBIO PHARMA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Secondary offering of 5,000,000 shares of common stock by selling stockholder KKR Genet | 2026-08-17 |
| Quarterly report · Q2 2026 BRIDGEBIO PHARMA, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product revenue Q2 2026: $222.4 million (vs. $71.5 million in Q2 2025) — 211% i | 2026-08-10 |
| Results announced · Q3 2026 BRIDGEBIO PHARMA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenues: $243.7 million (vs. $110.6 million in Q2 2025) • Attru | 2026-08-10 |
| Company announcement · Q3 2026 BRIDGEBIO PHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: BridgeBio Pharma, Inc. (Ticker: BBIO, Listed on Nasdaq Global Select Market) • | 2026-07-22 |
| Quarterly report · Q1 2026 BRIDGEBIO PHARMA, INC. — Q1 2026 SUMMARY HEADLINE NUMBERS • Net product revenue: $180.6 million (Q1 2026) vs. $36.7 million (Q1 2025) — 391% increas | 2026-05-07 |
| Proxy statement · Q2 2026 BRIDGEBIO PHARMA, INC. — 2026 ANNUAL MEETING PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Three Directors — Vote for Jame | 2026-04-24 |
| Annual report FY2025 BRIDGEBIO PHARMA, INC. — 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Market capitalization (non-affiliate): $7.3 billion as of June 30, 2025 • Shares | 2026-02-24 |
Readable in the app.
| Announcement | Date |
|---|---|
| Company raises $933.9M in preferred stock investment from multiple investors BridgeBio Pharma raised $933.9 million on July 1, 2026, by issuing preferred stock to two investors: Sixth Street Partners ($800M for 800,000 shares) and KKR affiliate HCRx ($133.9M for 133, | 2026-07-02 |
| NDA submitted to FDA for encaleret for ADH1 treatment BridgeBio Pharma submitted a New Drug Application (NDA) to the FDA for encaleret, a potential first-in-class treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic calci | 2026-05-13 |
| Board approves $500 million stock repurchase program BridgeBio Pharma reported Q1 2026 financial results on May 7, 2026. The 8-K filing does not disclose specific financial metrics, revenue figures, or operational details—these were included i | 2026-05-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BridgeBio Pharma Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.